If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Morand is Head of the School of Clinical Sciences at Monash Health, Monash University's largest clinical school, and a physician-scientist. 

He is a clinical rheumatologist, and Head of the Monash Health Rheumatology Unit, the largest in Australia. He specialises in research and clinical care of systemic lupus erythematosus, as well as complex rheumatic diseases and rheumatoid arthritis. He is founder of the Monash Lupus Clinic, Australia's largest research-grounded clinic for patients with SLE, a founding member of the Australian Lupus Registry & Biobank, and Chair of the AsiaPacific Lupus Collaboration. 

His lab at Monash has studied the biology of glucocorticoids in rheumatic disease and lupus since 1996. 

Research interests

Professor Morand's is a physician-scientist whose key interests are clinical outcome measurement and biological profiling in SLE, and the actions of glucocorticoid induced proteins on the immune system. Read more at https://www.monash.edu/medicine/scs/research/cid/rheumatology/researchers/eric-morand 

His group has pioneered the development of treat-to-target outcome measures in SLE, via the AsiaPacific Lupus Collaboration, which has over 1800 patients under study. 

Biomarker studies in SLE are also a major interest, with 000s of samples linked to longitudinal clinical data archived in the Australian Lupus Registry & Biobank, headquartered at Monash. 

His lab discovered the role in rheumatic disease of multiple important glucocorticoid-regulated proteins. Most recently his group defined the role of GILZ in RA, Th17 pathways, B cell activation, and lupus, and are working on exploiting its actions to develop a safe glucocorticoid mimic. His lab also works on innate immunity including the actions of the unique pro-inflammatory protein, MIF. 

Clinical activities

Professor Morand is Head of Rheumatology, Monash Health. He works in clinics servicing lupus, rheumatoid arthritis, and complex rheumatology cases, and undertakes ward duty inpatient care in the largest service in the country. 

Consulting

Advisory expertise and research collaboration experience with international biotech and Pharma companies including AstraZeneca, Janssen, BMS, UCB, Pfizer, Eli Lilly, GSK, CSL. 

 

Special interests include Lupus / SLE outcome measures, trials, translational research and biomarkers. 

Community service

Professor Morand is a Board member of Rare Voices Australia, has served on the board of the Australian Rheumatology Association and is a member of the Scientific Advisory Board of the ARA Research Trust. 

Research area keywords

  • Systemic Lupus Erythematosus
  • glucocorticoids
  • Lupus
  • SLE
  • RA
  • GILZ
  • MIF
  • Rheumatoid Arthritis
  • Rheumatology
  • outcome measures
  • Clinical Trials
  • Translational Research
  • Cytokines

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2000 2022

Research Output 1990 2019

1 Citation (Scopus)

Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosis

Lin, E., Vincent, F. B., Sahhar, J., Ngian, G-S., Kandane-Rathnayake, R., Mende, R., Morand, E. F., Lang, T. & Harris, J., 1 Jan 2019, In : Clinical and Translational Immunology. 8, 4, 11 p., e1045.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Attainment of the lupus low disease activity state is associated with protection from damage accrual in patients with active disease at baseline

Golder, V., Morand, E. F., Kandane-Rathnayake, R., Huq, M., Nim, H., Louthrenoo, W., Luo, S. F., Wu, Y-J., Lateef, A., Sockalingam, S., Navarra, S. T. V., Zamora, L., Hamijoyo, L., Katsumata, Y., Harigai, M., Chan, M., O’Neill, S., Goldblatt, F., Sing Lau, C., Li, Z. & 2 others, Hoi, A. & Nikpour, M., 2019, p. 203-203. 1 p.

Research output: Contribution to conferenceAbstractOtherpeer-review

Comparison of effects of DORIS remission and lupus low disease activity state (LLDAS) on disease outcomes in a multinational prospective study

Morand, E., Golder, V., Kandane-Rathnayake, R., Huq, M., Nim, H., Louthrenoo, W., Luo, S. F., Lateef, A., Sockalingam, S., Navarra, S., Hamijoyo, L., Katsumata, Y., Chan, M., Hoi, A. & Nikpour, M., 2019. 1 p.

Research output: Contribution to conferenceAbstractOtherpeer-review

Could GILZ be the answer to glucocorticoid toxicity in lupus?

Flynn, J. K., Dankers, W. & Morand, E. F., 17 Jul 2019, In : Frontiers in Immunology. 10, JULY, 13 p., 1684.

Research output: Contribution to journalReview ArticleResearchpeer-review

Open Access
File

Prizes

Dean's Award for Research (Enterprise)

Eric Morand (Recipient), 1 Aug 2018

Prize: Prize (including medals and awards)

Distinguished Innovator Award, Lupus Research Alliance

Eric Morand (Recipient), 2015

Prize: National/international honour

Paper selected for the Best of Immunology & Cell Biology (ICB)/ Clinical and Translational Immunology (CTI) Workshop at the 2019 Australian & New Zealand Society for Immunology (ASI) Annual Scientific Meeting

Fabien Vincent (Recipient), James Harris (Recipient), Eric Morand (Recipient), Joanne Sahhar (Recipient), Gene Ngian (Recipient), Rangi Kandane-Rathnayake (Recipient), Tali Lang (Recipient), Emily Lin (Recipient) & Rachel Mende (Recipient), 11 Dec 2019

Prize: Prize (including medals and awards)

Parr Prize for Research, Australian Rheumatology Association

Eric Morand (Recipient), 2001

Prize: Prize (including medals and awards)

Supervisor of the Year

Eric Morand (Recipient), 2011

Prize: Prize (including medals and awards)